Viatris

“From the Biocon perspective, we received the $400 million of cash.”

Viatris is monetizing its Biocon holding, receiving $400 million of cash (with associated taxes), adding to deployable capital.

“While Vertex has been launching, I think, have a different timeframe in mind, we have a different strategy.”

Viatris positions its fast-acting meloxicam against Vertex in the non-opioid acute pain market, differentiating on pricing and physician targeting strategy.

“We targeted accretive regional business development, completing 60 regional transactions, including our acquisition of Aculys Pharma in Japan.”

Viatris acquired Aculys Pharma in Japan as part of accretive regional business development to strengthen its Japan CNS portfolio.

“with the shift of commercial rights from Pfizer back to us”

Viatris regained EpiPen commercial rights in Canada from Pfizer, relaunching the product and contributing to EpiPen strength.

“We are excited about our recent acquisition of Aculys Pharma in Japan, adding 2 innovative CNS assets, pitolisant and spydia to our portfolio.”

Viatris acquired Aculys Pharma in Japan, adding CNS assets pitolisant and spydia to build out its innovative brands portfolio.

“what's the strategy to build this market where AbbVie was unable to with annuity”

Analyst frames AbbVie as having failed to build the presbyopia eye-drop market (with Vuity), setting up Viatris's competing MR-141; a negative read-through for AbbVie's effort in the category.

“As previously discussed, in Q1, we entered into agreement with our partners from Idorsia that allows us even greater control over the Selatogrel and Cenerimod development programs and expands our geographic ownership of Cenerimod.”

Viatris expanded its licensing partnership with Idorsia, gaining greater development control and broader geographic rights to Cenerimod, a positive read-through for the scope of Idorsia's out-licensing arrangement.

“We are now collaborating with our partner Lexicon to explore next steps, including a potential label expansion to increase patient access as we continue to remain on track for our regulatory submissions starting in 2025 in key ex-U. S. Markets.”

Viatris and partner Lexicon are pursuing a potential label expansion for sotagliflozin and advancing ex-U.S. regulatory submissions starting in 2025 — a modest positive signal for Lexicon's SGLT1/2 inhibitor franchise.

“To preserve the ongoing continuity of the development programs for selatogrel, cenerimod, we have updated certain terms of our original global research and development collaboration with Idorsia.”

Viatris amended its R&D collaboration with Idorsia, assuming more of the remaining development cost obligation for selatogrel and cenerimod in exchange for added territory rights and reduced milestone payments — Idorsia trades near-term milestone economics for Viatris taking fuller control of late-stage development.